Nov 08, 2022 / 10:35PM GMT
Rich Law -
All right. Let's get started. Good afternoon. My name is Rich Law, I'm a Senior Biotech Analyst at CS. For the next session, I'd like to welcome Sangamo to join -- and this will be a presentation followed by a fireside chat. And we're joined by Mark McClung, COO of the company.
So thank you for coming. A pleasure to be hosting you. So I'll turn it over to you for the presentation.
D. Mark McClung - Sangamo Therapeutics, Inc. - Executive VP & COO
All right. Thanks, Rich, and thanks for those of you that are joining us today. So let me get right into it. I apologize, we were a little late in getting over here. These are our forward-looking statements.
So Sangamo Therapeutics, we think, is a very interesting company. We're founded and really our vision is to become a genomics medicine company. Many of you know that core to Sangamo is our zinc finger editing capability that the company has been working on for many years. And with that, we've had a number of the first. And I think that really gives us the desire to continue to make sure that
Sangamo Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers